Dr. Mouquet earned a BS in Biochemistry, a MS in Biochemistry & Molecular Biology and a PhD in Immunology from the University of Rouen (Normandy, France). He performed his post-doctoral trainee in the laboratory of Michel C. Nussenzweig at the Rockefeller University (2007-2013), where he studied B-cell antibody response to HIV-1, isolated and characterized HIV-1 bNAbs. In 2013, Hugo started his group as a young investigator in the immunology department of the Institut Pasteur, supported by an ERC starting grant award. He currently heads the laboratory of Humoral Immunology at the Institut Pasteur. His lab investigates the humoral responses to pathogens in humans with a focus on HIV-1, Hepatitis viruses and emerging infections, and a dual interest in basic and translational research.
Antibody memory B-cell response to Chikungunya virus
Chikungunya is a mosquito-transmitted disease of sub-tropical areas caused by an alphavirus, the Chikungunya virus (CHIKV). CHIKV infection has re-emerged after several decades causing large outbreaks, making it an important public health concern. The […]
Humoral immunoprofiling in HIV-1 post-treatment controllers
Rare infected individuals who initiated antiretroviral therapy (ART) very early during primary infection can enter in remission after its interruption, a phenomenon known as post-treatment control. Interestingly, early treatment has been associated with the […]
Humoral immune response & immunotherapy in HBV infection
Human infections caused by hepatitis B virus (HBV) are major healthcare issues. Despite available effective vaccines, more than 250 million individuals worldwide are chronically infected by HBV, which accounts for approximately 1 million deaths […]
Humoral immunity & human monoclonal antibodies against SARS-CoV-2
The objective of this research project is to understand the molecular and functional basis of the memory B-cell antibody response to the SARS-CoV-2 Spike protein. One of the key goals of this research program […]
Archive of the Group for AIDS Research
This page contains the list of past meetings held by the Group for AIDS Research (Groupe de Réflexion SIDA) of the Pasteur Institute since 2014. The list of previous meetings held since 2002 can […]
Group for AIDS Research
The Group for AIDS Research (Groupe de Réflexion SIDA, GRS) organizes bimonthly meetings and seminars around an HIV / AIDS research topic. Meetings and seminars are open to all. Meetings are usually held on […]
Intestinal and IgA B-cell responses to HIV-1
Mucosal transmission of HIV-1 can induce a local production of IgG and IgA antibodies predominantly targeting the gp41 subunit of the viral envelope glycoprotein gp160. However, whether they limit viral dissemination upon HIV-1 exposure […]
Clonal B cells in HCV-induced cryoglobulinemia vasculitis
Hepatitis C virus (HCV) infection can trigger the development of autoimmune disorders among which, cryobulininemic vasculatitis is the most prevalent. HCV-associated cryobulininemic vasculatitis is mediated by mono-/oligo-clonal IgM cryoglobulins with rheumatoid factor activity, thought […]
Antiviral properties of broadly neutralizing HIV-1 antibodies
Broadly neutralizing HIV-1 antibodies (bNAbs) can develop in rare infected individuals several years after co-evolution with diversifying viruses. In animal models, passive immunotherapy with potent HIV-1 bNAbs has been shown to protect from infection […]
Human Antibody Responses to Viruses Adaptive immune responses naturally occurring upon infection or induced by vaccination generate high affinity antibodies, and memory B-cell subsets to respond to further antigenic challenges, providing protection against (re-)infections. […]
2021Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies., Cell Rep Med 2021 Apr; (): 100275.
2021Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis., PLoS Pathog 2021 Apr; 17(4): e1009526.
2021Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies., Nat Med 2021 Mar; (): .
2021Sex differences in the evolution of neutralizing antibodies to SARS-CoV-2., J Infect Dis 2021 Mar; (): .
2020Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models., Cell Host Microbe 2021 Feb 10;29(2):236-249: .
2020TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice., PLoS Pathog 2020 Nov; 16(11): e1009025.
2020Antibody Neutralization of HIV-1 Crossing the Blood-Brain Barrier., mBio 2020 Oct; 11(5): .
2020Syncytia formation by SARS-CoV-2-infected cells., EMBO J 2020 12; 39(23): e106267.
2020A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations., Sci Transl Med 2020 09; 12(559): .
2020Binding mechanisms of therapeutic antibodies to human CD20., Science 2020 Aug; 369(6505): 793-799.
+View full list of publications